Interestingly, the mechanism may be more than just weight loss
While Canada was the first to lose patent protection for semaglutide in January, the Canadian health regulator hasnt approved any generics so far effectively making India the first major market to see a flood of copycat versions
Drucker, adding that it is important for clinicians to have a conversation with their patients about potential gallbladder events, especially in those with a history of gallbladder disease
GLP-1 receptor agonists are medications used to treat type 2 diabetes and obesity by mimicking the glucagon-like peptide 1 hormone
Bio-stimulatory injectables stimulate the bodys natural collagen production, making them an excellent option for patients experiencing skin laxity from weight loss
Blood glucose control: In patients with type 2 diabetes, improvements in HbA1c levels and fasting glucose have been observed, reflecting enhanced insulin sensitivity and glucose regulation
